| Officer | Age | In this role | 2025 pay | Source |
|---|---|---|---|---|
|
Amy Elazzouzi
interim principal financial officer
Title from the Form 8-K dated Sep 2, 2026
|
Not stated | Not stated | Not reported | |
|
Susan Abu-Absi
Chief Operating Officer
Title from the Form 4 dated Sep 1, 2026
|
Not stated | Not stated | Not reported | |
|
J. Jill Hopkins
Chief Medical Officer and President of Research and Development
|
61 |
Since 2023
3 years
|
$2,188,965 | |
|
Mark Plavsic
Chief Technology Officer
|
65 |
Since 2023
3 years
|
Not reported | |
|
Julie Person
Chief People Officer
Title from the Form 4 dated Sep 1, 2026
|
Not stated | Not stated | Not reported | |
|
Anthony Gibney
See Remarks
Title from the Form 4 dated Jun 16, 2026
|
55 | Not stated | $2,751,226 | |
|
Conor Kilroy
See Remarks
Title from the Form 4 dated Jul 1, 2026
|
44 | Not stated | Not reported | |
|
Erica Kratz
Chief Reg. & Quality Officer
Title from the Form 4 dated Sep 1, 2026
|
Not stated | Not stated | Not reported | |
|
Natalie Holles
Also a director
See Remarks
Title from the Form 4 dated May 19, 2026
|
Not stated | Not stated | Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
From the proxy statement filed Apr 20, 2026 · updated by the 8-Ks of May 4, 2026 and Jul 8, 2026
| Director | Age | On board | Independent | Committees | Other public boards | 2025 pay | Source |
|---|---|---|---|---|---|---|---|
|
David Johnson
Board chair
|
61 |
2021
5 years
|
Independent |
Nominating and Corporate Governance Committee
|
Zentalis Pharmaceuticals, Inc. | $235,331 | |
|
Elisabet de los Pinos
CEO
|
53 |
2009
17 years
|
Not independent | None stated | None stated | Paid as CEO | |
|
Natalie Holles
Joined Apr 30, 2026
CEO
|
- | - | - | - | - | Paid as CEO | |
|
Giovanni Mariggi
|
41 |
2019
7 years
|
Independent |
Audit Committee
Compensation Committee · Chair
|
Fore Biotherapeutics US Inc., Vaderis Therapeutics AG, Curevo Inc., Vicebio Ltd. | Not stated | |
|
Antony Mattessich
|
59 |
2021
5 years
|
Independent |
Audit Committee
Nominating and Corporate Governance Committee · Chair
|
None stated | $214,891 | |
|
Sapna Srivastava
|
55 |
2021
5 years
|
Independent |
Audit Committee · Chair
|
Nuvalent, Inc., Alumis, Inc. | Not stated | |
|
Teresa Marie Bitetti
|
63 |
2025
1 year
|
Independent |
Compensation Committee
|
Osmol Therapeutics, Inc. | $283,562 | |
|
Jeremy Bender
Joined Jul 7, 2026
|
- | - | Independent |
Compensation Committee
Nominating and Corporate Governance Committee
|
- | - | |
|
Karan Takhar
Leaving at the meeting
|
Not stated | Not stated | Independent |
Compensation Committee
Nominating and Corporate Governance Committee
|
None stated | Not stated |
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.
The proxy filed Apr 20, 2026 describes a review policy but reports no transactions.
Read the policy in the proxyLoading...